文献类型：期刊文献

英文题名：Pathologic complete response after Sintilimab combined with FOLFOX therapy in MSI-H type patients with locally advanced GC: a case report

作者：Wang, Xiaoke[1,2];Gu, Yuanhui[1];Yi, Lin[3];Wu, Tao[1,3];Wang, Ling[4];Tian, Jiao[3];Lu, Yuyuan[3];Jin, Penghui[2];Yang, Xin[2];Yang, Yan[5]

第一作者：Wang, Xiaoke

通信作者：Yang, Y[1]

机构：[1]Gansu Prov Hosp, Dept Gen Surg, Lanzhou, Gansu, Peoples R China;[2]Gansu Univ Chinese Med, Sch Clin Med 1, Lanzhou, Gansu, Peoples R China;[3]Gansu Univ Chinese Med, Sch Tradit Chinese & Western Med, Lanzhou, Gansu, Peoples R China;[4]Gansu Prov Hosp, Dept Pathol, Lanzhou, Gansu, Peoples R China;[5]Gansu Prov Hosp, Dept Pharm, Lanzhou, Gansu, Peoples R China

第一机构：Gansu Prov Hosp, Dept Gen Surg, Lanzhou, Gansu, Peoples R China

通信机构：[1]corresponding author), Gansu Prov Hosp, Dept Pharm, Lanzhou, Gansu, Peoples R China.

年份：2025

卷号：15

外文期刊名：FRONTIERS IN ONCOLOGY

收录：;Scopus(收录号：2-s2.0-105005785701);WOS:【SCI-EXPANDED(收录号:WOS:001492005100001)】；

基金：The author(s) declare that financial support was received for the research and/or publication of this article. National Natural Science Foundation of China, No. 82160842; Gansu Youth Science and Technology Fund program, No. 21JR7RA643; Gansu Provincial People's Hospital youth cultivation project, No. 20GSSY4-22; Natural Science Foundation of Gansu Province, No. 23JRRA1773 and Natural Science Foundation of Gansu Province, No. 24JRRA590.

语种：英文

外文关键词：advanced gastric cancer; MSI-H; PCR; immunotherapy; case report

摘要：As one of the most common gastrointestinal tumors, Gastric Cancer (GC) poses a serious threat to human health due to its high morbidity and mortality. The current treatment strategy is a comprehensive treatment program mainly based on surgery, especially for advanced GC patients. The emergence of immune checkpoint inhibitors has completely changed this status quo, and the synergistic effect of neoadjuvant immunotherapy combined with chemotherapy has significantly improved the resection and radical rate and overall survival of patients with advanced local GC. We present a case of locally advanced GC (cT4N0Mx) with microsatellite instability high (MSI-H) and PD-L1 Combined Positive Score (CPS)=2. The patient received neoadjuvant therapy with Sintilimab combined with FOLFOX (folinic acid (leucovorin), 5-fluorouracil (5-FU), and oxaliplatin), and significantly reduced tumor volume after 3 cycles of treatment. Then she underwent subtotal gastrectomy with gastrojejunostomy and D2 lymph node dissection. The postoperative pathological results showed that no cancerous tissue remained in the tumor tissue, and pathologic complete response (pCR) was achieved. The first cycle of adjuvant therapy with the same protocol was received after surgery. During adjuvant therapy, patients mainly experienced side effects such as dyspepsia, nausea and mild myelosuppression. Therefore, immunotherapy with Sintilimab combined with FOLFOX chemotherapy has the potential to be an effective treatment option for patients with resectable locally advanced MSI-H GC.